SoVote

Decentralized Democracy

House Hansard - 330

44th Parl. 1st Sess.
June 12, 2024 02:00PM
Context: House Hansard - 330 - Jun/12/24
Mrs. Tracy Gray (Kelowna—Lake Country, CPC)
  • Jun/12/24 4:08:45 p.m.
  • Watch
Madam Speaker, I am rising to table a petition on behalf of residents from my community of Kelowna—Lake Country and the surrounding region. To summarize, cystic fibrosis is the most common fatal genetic disease, affecting 4,338 Canadian children and young adults, and there is no cure. Trikafta is a life-changing medicine that treats the basic defect of cystic fibrosis, not just the symptoms. It can treat almost 95% of Canadians with cystic fibrosis, but not all can access it. Therefore, petitioners are calling on the Government of Canada to, first, improve access to rare disease medications by empowering Health Canada to expedite use of patient and laboratory in vitro data to expand access to drugs for rare diseases mutations where clinical trials are not feasible, and second, develop a regulatory model that would permit bulk approvals of gene mutations that can respond to precision medicines such as Trikafta.
152 words
  • Hear!
  • Rabble!
  • star_border